Company will feature its CorPath System during American College of Cardiology Annual Meeting, Mar. 29-31
Waltham, MA – March 26, 2014 (Booth # 1343) – Corindus Vascular Robotics, the leader in precision vascular robotics, will showcase its FDA-cleared CorPath System at the upcoming American College of Cardiology (ACC) annual meeting, March 29–31 in Washington, D.C. The CorPath is the first medical device to bring robotic precision and accuracy to coronary angioplasty to help optimize clinical outcomes. Corindus representatives will be onsite to conduct demos of the CorPath System and answer questions about the significant advantages in procedure precision and improvements in clinical outcomes made possible by robotics in the cath lab.
As a leader in the robotic space, Corindus has seen 300 percent growth in customer installs since spring of 2013. In late-2013, Corindus successfully installed a CorPath system at Orlando Regional Medical Center (ORMC), the first in Florida, as well as the first CorPath in a hospital within the Carolinas, and the second system in New York State. The adoption of the CorPath system continues to grow steadily and several customers now have two or more CorPath systems installed. CorPath systems are installed across the United States with several more pending within the next few months.
According to ORMC’s Dr. Vijaykumar S. Kasi, “The robotic system fundamentally changes how cath lab procedures are performed. As an interventional cardiologist, I am particularly excited with how this technology is improving the placement precision of guidewires, stents and balloons in patients and reducing physician radiation exposure.”
“The basic technique used in coronary angioplasties has remained largely the same since the first stent procedure was performed in 1986,” said David Handler, President and CEO of Corindus Vascular Robotics. “The introduction of robotic-assisted systems offers interventional cardiologists improvements in their ability to perform the procedure with enhanced precision, seated in a radiation-protected cockpit. We have found physicians to be extremely receptive to this technology due to the precision and effectiveness of stent placement – and their positive feedback is a testament to the incredible growth we’ve seen over the last year.”
Most recently, Corindus announced a partnership with Sanford Health and The Leona M. and Harry B. Helmsley Charitable Trust to launch a technical feasibility investigation for a remote robotics program. The program is intended to empower an interventional cardiologist at a major center to robotically control the movement of interventional devices at a remote facility.
“We are committed to pioneering a positive change in the delivery of heart care and making a significant impact for patients,” continued Handler.
For a demonstration of robotic angioplasty with the CorPath System, register here and visit them at ACC at booth #1343.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event
Examples of such statements include statements: